[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100458299":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":30,"centralContacts":35,"locations":10,"responsibleParty":45,"collaborators":48,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":63,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":84,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":10},{"fullName":5,"class":6},"RWTH Aachen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients admitted to interdisciplinary polypharmacy consultation service",null,"Patients admitted to the Interdisciplinary Polypharmacy Consultation Service of the Department of Geriatric's University Outpatient Clinic in cooperation with the Institute of Clinical Pharmacology",[13,14,15],"Genetic: Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolism","Other: Adverse Drug Reaction detection","Other: Falls Efficacy Scale International (FES-I)",[17,22,26],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"GENETIC","Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolism","All planned interventions are explorative analyses of biological and genetic risk profiles that can contribute to patients' individual risk for adverse drug reactions, i.e. due to variability in drug metabolism",[9],{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"Adverse Drug Reaction detection","During appointments in the university outpatient clinic, patients will undergo a comprehensive adverse drug reaction (ADR) assessment based on an ADR diary they were handed at enrolment",[9],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"Falls Efficacy Scale International (FES-I)","The FES-I wil be obtained to estimate fear of falling",[9],[31],{"name":32,"affiliation":33,"role":34},"Julia C. Stingl, MD, ScD","Institute of Clinical Pharmacology, University Hospital RWTH Aachen","PRINCIPAL_INVESTIGATOR",[36,42],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Mathias Freitag","CONTACT","+492417501116","+492418089134","mfreitag@ukaachen.de",{"name":32,"role":38,"phone":43,"phoneExt":10,"email":44},"+492418089130","jstingl@ukaachen.de",{"type":34,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Julia Stingl","Univ.-Prof. Dr. med.",[49],{"name":50,"class":6},"B. Braun Foundation","100458299","individual-risk-profiles-for-adverse-drug-reactions-in-geriatric-patients-100458299",false,"NCT05247814","Individual Risk Profiles for Adverse Drug Reactions in Geriatric Patients","Individual Patient Risk Profiles for Adverse Drug Reactions: Establishing a Consecutive Research Cohort in an Interdisciplinary Polypharmacy Consultation Service of a Geriatric University Outpatient Department","Inclusion Criteria:\n\n* 70 years or older\n* Current drug therapy with three or more drugs\n* Being a patient in the interdisciplinary polypharmacy consultation service of the geriatric university outpatient clinic\n* Sufficient mobility (minimum: Wheelchair mobility)\n* Written informed consent of the patient or the legal representative\n\nExclusion Criteria:\n\n* No sufficient communication possible\n* Patients classified as terminally ill by the medical staff\n* Patients, that are incapable to give their informed consent and who do not have a legal representative","ALL","70 Years",{"count":61,"type":62},2000,"ESTIMATED","6 Months","OBSERVATIONAL","This project will generate a prospective cohort of geriatric patients with polypharmacy which will be characterized for vulnerability profiles of adverse drug reactions.",[67,68,69,70],"Polypharmacy","Pharmacogenetics","Pharmacogenomic Testing","Drug-Related Side Effects and Adverse Reactions",[72,73,74,75,76,77,78,79,80,81,82,83],"Geriatric Assessment","Medication Adherence","Aged","Aged, 80 and over","Medication therapy management","Pharmacists","Geriatricians","Clinical Pharmacology","Medication reconciliation","Hospital pharmacy services","Hospital outpatient clinics","nterdisciplinary Health Team","NOT_YET_RECRUITING","2022-06-17",{"date":87,"type":88},"2022-06-23","ACTUAL",{"date":90,"type":62},"2022-07",{"date":92,"type":62},"2032-02",{"name":5,"class":6}]